Search

The microstructure and hardness of Ti-6Al-4V alloys were evaluated before and after aging to investigate the effect of the cooling rate at the solution treatment stage of the solution treatment and aging (STA) process for aerospace components. The cooling rate distribution across a Ti-6Al-4V alloy sample representing practical STA process of an aerospace fan disk component was estimated using finite element analysis. The Ti-6Al-4V alloy specimens were solution-treated with the obtained cooling rates, and aged. Experimental WQ of the Ti-6Al-4V alloy specimen in the solution treatment facilitated the retention of the primary α phase, while the β phase was transformed to α′. Controlled cooling at slower rates compared to WQ led to the formation of coarser globular α and the transformation of β to α+β lamellae. Subsequent aging of the specimens led to the observation of α+β lamellae in all specimens regardless of the cooling conditions, where the average thickness of the plates in lamellae was higher at slower cooling rates. The specimens exhibited higher hardness values when cooled more quickly at the solution treatment, which was attributed to the formation of thinner α plates and/or a higher α′ fraction. The hardness value of all specimens increased further after aging, regardless of the cooling conditions, due to precipitation of Ti3Al in the α phase and/or fine α plates from the α′ phase. [ABSTRACT FROM AUTHOR]

Numerous studies have analysed the clinical efficacies of hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS). However, reports that compare the two HMAs, decitabine and azacitidine, in patients with lower-risk (low and intermediate-1) MDS are limited. We compared 5-day decitabine and 7-day azacitidine regimens in terms of treatment responses, survival outcomes, and adverse events in patients with lower-risk MDS with poor prognostic features. The overall response rates (ORRs) were 67.2% and 44.0% in the patients treated with decitabine and azacitidine, respectively (P = 0.014). While the median progression-free survival (PFS) was significantly better in the patients treated with decitabine than in those treated with azacitidine (P = 0.019), no significant differences in event-free and overall survival rates were observed between the two groups. Multivariate analysis revealed that compared with azacitidine treatment, decitabine treatment is significantly associated with a higher ORR (P = 0.026) and longer PFS (P = 0.037). No significant differences were observed in the incidence of grade 3 or higher haematologic adverse events in response to the two HMAs. In conclusion, in lower-risk MDS, especially with poor prognostic features, ORR and PFS were significantly better with 5-day decitabine treatment than with 7-day azacitidine treatment, with comparable safety. [ABSTRACT FROM AUTHOR]